Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Argent Biopharma ( (AU:RGT) ) just unveiled an announcement.
Argent Biopharma Limited has notified the market of the issue of 2,500,000 unquoted performance rights under its employee incentive scheme. The new securities, which will not be quoted on the ASX, were issued on March 20, 2026, and are intended to support staff retention and alignment of employee interests with long-term shareholder value.
The issuance of these performance rights expands Argent Biopharma’s pool of equity-based incentives without immediate dilution in the quoted share capital. This move underscores the company’s use of compensation structures common in the biotechnology sector to attract and retain key talent amid competitive industry conditions.
The most recent analyst rating on (AU:RGT) stock is a Hold with a A$0.04 price target. To see the full list of analyst forecasts on Argent Biopharma stock, see the AU:RGT Stock Forecast page.
More about Argent Biopharma
Argent Biopharma Limited is a biotechnology company listed on the ASX under the code RGT. The company operates in the biopharmaceutical sector, focusing on developing and commercializing drug candidates and related therapies for medical markets.
Average Trading Volume: 192,762
Technical Sentiment Signal: Strong Sell
Current Market Cap: A$3.96M
Learn more about RGT stock on TipRanks’ Stock Analysis page.